Controlled Substance Prescribing And Fraud Overlap: When Opioid Cases Become Financial Crimes
A controlled substance investigation can move quickly from a review of prescribing decisions into a full financial crime prosecution. For physicians, clinic owners, pharmacists, executives, and licensed providers, the danger is not limited to whether a prescription was appropriate. Federal agents may begin with opioid prescribing patterns, then expand into billing records, Medicare and Medicaid claims, patient charts, pharmacy data, toxicology testing, referral relationships, compensation agreements, and internal communications.
That expansion changes the case. A provider who believes the government is questioning medical judgment may later face allegations that the practice billed for unnecessary services, submitted false claims, received improper referral compensation, or used prescriptions to support a broader revenue scheme. When prosecutors connect opioid prescribing to reimbursement, the investigation stops being only a controlled substance case. It becomes a white-collar criminal case built around money, intent, documentation, and alleged financial motive.
Opioid Prescribing Investigations Can Become Financial Crime Cases
Federal prosecutors rarely look at opioid prescribing in isolation. Once investigators identify a prescribing pattern they believe is suspicious, they often ask how the practice made money, who paid for the services, whether insurers were billed, and whether related testing, procedures, or referrals generated revenue. That financial inquiry can place the provider, the clinic, the billing company, and related business entities under scrutiny.
For medical professionals facing this kind of investigation, early defense strategy matters because the government may be building more than one theory at once. A provider may need to challenge both the allegation that prescriptions were issued outside the usual course of professional practice and the allegation that related claims were fraudulent. Working with an experienced Orlando white collar crime lawyer can help providers confront the prescribing evidence, billing evidence, and intent allegations before prosecutors control the narrative.
The Controlled Substance Allegation Is Only One Part of the Case
Federal law allows licensed practitioners to prescribe controlled substances when the prescription is issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. That rule is reflected in 21 C.F.R. § 1306.04, and it is central to criminal cases involving opioid prescribing. Prosecutors may argue that a physician crossed the line from treatment into unlawful distribution under 21 U.S.C. § 841.
The defense often begins with the medical record, but it cannot end there. Chronic pain treatment involves difficult clinical judgments, complicated patient histories, failed prior treatment, medication tolerance, mental health issues, substance use concerns, and ongoing monitoring decisions. Poor charting, aggressive prescribing, high patient volume, or disagreement among experts does not automatically prove that a provider acted with criminal intent. The government must prove far more than imperfect medicine.
Billing Records Give Prosecutors a Second Theory
Once reimbursement records enter the investigation, prosecutors may use billing data to argue that the provider was not simply prescribing improperly, but profiting from medically unnecessary care. Office visits, urine drug screens, injections, imaging, durable medical equipment, pharmacy claims, and telehealth encounters can all become part of the alleged fraud theory. A visit connected to a disputed prescription may be treated as a false claim if prosecutors argue that the underlying care was not legitimate.
Health care fraud charges under 18 U.S.C. § 1347 focus on schemes to defraud a health care benefit program or obtain money through false or fraudulent representations. In opioid-related prosecutions, the government may claim that Medicare, Medicaid, TRICARE, private insurers, or pharmacy benefit programs paid claims tied to improper prescribing. That theory can increase the provider’s exposure through restitution demands, forfeiture allegations, sentencing enhancements, licensure consequences, and exclusion from federal health care programs.
Data Patterns Do Not Prove Criminal Intent
Opioid investigations often start with numbers. Investigators may examine prescription volume, dosage levels, combinations involving opioids and benzodiazepines, cash-pay patients, out-of-area patients, pharmacy refusals, refill timing, repeated diagnostic codes, and the use of testing or ancillary services. Billing data may then be compared against patient charts to argue that visits were brief, documentation was thin, drug testing was excessive, or prescriptions continued despite warning signs.
Numbers can support an investigation, but numbers do not prove guilt by themselves. A pain management practice will naturally look different from a primary care office. A provider treating complex chronic pain patients may prescribe more controlled substances than a physician who rarely encounters those conditions. High utilization of testing or monitoring can reflect clinical caution rather than fraud. The defense must force prosecutors to move beyond pattern evidence and prove the provider knowingly joined a criminal scheme.
Medical Necessity Disputes Can Be Reframed as Fraud
Many opioid-related financial crime cases depend on turning medical necessity disputes into criminal allegations. Prosecutors may argue that visits, testing, procedures, prescriptions, or referrals were designed to generate revenue instead of treating patients. The government may rely on experts, patient interviews, payer rules, and billing spreadsheets to claim that the entire treatment model was fraudulent.
That framing must be challenged carefully. Medical necessity is not always obvious from a billing code or a short chart excerpt. Chronic pain patients may present with complex histories, incomplete prior records, inconsistent symptoms, medication tolerance, or legitimate reasons for closer monitoring. An Orlando white-collar crime lawyer defending a provider in this setting must be able to connect clinical decision-making, patient-specific facts, payer rules, and billing practices into one defense. The case is not only about what was prescribed. It is about why the provider made those decisions and what the government can actually prove.
Ruan Strengthened the Focus on Knowledge and Intent
The Supreme Court’s decision in Ruan v. United States is critical in controlled substance prescribing cases. Once a defendant produces evidence that the prescribing was authorized, the government must prove beyond a reasonable doubt that the defendant knowingly or intentionally acted in an unauthorized manner. That standard matters because criminal liability cannot rest only on negligence, mistake, poor documentation, or a later disagreement with a physician’s medical judgment.
Ruan does not stop prosecutors from bringing opioid cases. It does force the government to prove the provider’s state of mind. In cases involving both prescribing and billing allegations, intent becomes the center of the case. Prosecutors may argue that financial gain explains the prescribing pattern. The defense must show where the government’s theory relies on assumptions, incomplete records, distorted data, or expert hindsight rather than proof of knowing criminal conduct.
Financial Relationships Can Create Additional Exposure
Opioid-related investigations may also involve referral arrangements, toxicology labs, pharmacies, telemedicine platforms, marketing companies, management agreements, and ownership interests in related businesses. Prosecutors may scrutinize whether compensation was tied to referrals, whether testing was ordered for financial reasons, or whether providers were used to support a larger billing operation.
Financial relationships should never be ignored in these cases. A contract, payment structure, referral pattern, or ownership interest that looks suspicious to investigators may have a legitimate business or clinical explanation. Compliance reviews, fair market value support, written agreements, medical necessity protocols, and communications about patient care can all become important. The government may treat money as evidence of motive, but motive is not the same as proof of fraud, and a business relationship is not automatically a criminal agreement.
The Defense Must Address Medicine and Money Together
A strong defense in an opioid-related fraud case must examine the clinical record and the financial record together. The defense team needs to understand the patient charts, prescription history, treatment protocols, billing submissions, coding practices, payer rules, staff responsibilities, compliance procedures, and communications among providers, billers, pharmacies, and related entities.
Separating the medical defense from the billing defense can leave the provider exposed. If the patient record supports the need for evaluation, monitoring, testing, and treatment, that evidence can weaken the government’s claim that the billing was fraudulent. If the billing evidence shows payer complexity, administrative delegation, coding disputes, or non-criminal error, that record can weaken the effort to portray the practice as a criminal enterprise. The defense must prevent prosecutors from turning every imperfect note, disputed prescription, or reimbursement claim into proof of fraud.
Contact The Baez Law Firm for Aggressive Defense
If you are a physician, clinic owner, pharmacist, executive, or licensed provider under investigation for opioid prescribing, billing fraud, controlled substance violations, kickbacks, or health care fraud, the government may already be reviewing far more than patient charts.
The Baez Law Firm defends clients in serious white collar, health care fraud, and criminal investigations involving complex government theories and severe personal consequences. Contact The Baez Law Firm today to speak with an experienced Orlando white collar crime lawyer about the prescribing, billing, and financial crime allegations involved in your case.
Source:
- 21 U.S.C. § 841 — Prohibited Acts A
law.cornell.edu/uscode/text/21/841 - 21 C.F.R. § 1306.04 — Purpose of Issue of Prescription
ecfr.gov/current/title-21/chapter-II/part-1306/subject-group-ECFR1eb5bb3a23fddd0/section-1306.04 - 18 U.S.C. § 1347 — Health Care Fraud
law.cornell.edu/uscode/text/18/1347 - Ruan v. United States, 597 U.S. 450 (2022)
supremecourt.gov/opinions/21pdf/20-1410_1an2.pdf - S. Department of Justice — Health Care Fraud Unit
- justice.gov/criminal/criminal-fraud/health-care-fraud-unit
